With a record 45 clinical trials either ongoing or starting up in 2016, research coordinators and principal investigators throughout the Therapeutics Development Network took time out in San Antonio recently to discuss clinical research and put attendees through boot camp.
Site Search
PTC Therapeutics has discontinued development of ataluren as a potential treatment for people with cystic fibrosis caused by a nonsense mutation. The Cystic Fibrosis Foundation is supporting efforts to pursue treatments for people with CF who have a nonsense, splicing or other rare mutations.
Dr. Skach discusses the latest advances in CF research and exciting new approaches to address the underlying cause of the disease.
It's that dreaded time again ... Cough, cough, sneeze ... Yuck! I'm prepared, though. And you can be too. Check out the top nine tips I swear by for staying healthy during cold and flu season.
For adult with CF Brent Pace, staying healthy isn't about avoiding life. It's about living mindfully.
Hear from John P. Clancy, M.D., the first plenary speaker at this year's NACFC, about recent advances in personalized medicine, which could allow clinicians to better tailor treatment to the individual with CF.
After what seems like an hour and too many clicks to count, you finally did it. You booked your flight! A couple weeks leading up to your departure date, panic starts to set in. You go into operation “no one better get me sick” mode.
The Foundation hosted a small conference that brought together CF scientists, clinical researchers, and biotechnology and pharmaceutical industry representatives. Learn more and watch a short video of attendees sharing their thoughts about the progress we are making in CF research.
The purpose of the Screening Improvement Program mechanism is to catalyze efforts aimed at improving the screening system used for early diagnosis.